Cogent Biosciences, Inc. (COGT)
Automate Your Wheel Strategy on COGT
With Tiblio's Option Bot, you can configure your own wheel strategy including COGT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol COGT
- Rev/Share 0.0
- Book/Share 1.9327
- PB 3.7408
- Debt/Equity 0.078
- CurrentRatio 5.1276
- ROIC -1.2219
- MktCap 823178880.0
- FreeCF/Share -1.9665
- PFCF -3.6943
- PE -3.0398
- Debt/Assets 0.0602
- DivYield 0
- ROE -0.9268
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | COGT | Scotiabank | -- | Sector Outperform | -- | $17 | March 7, 2025 |
| Downgrade | COGT | Needham | Buy | Hold | -- | -- | Dec. 11, 2024 |
News
Wall Street Analysts Believe Cogent Biosciences (COGT) Could Rally 224.37%: Here's is How to Trade
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 224.4% upside potential for Cogent Biosciences (COGT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
65% mean improvement in Total Symptom Score (TSS) at 48 weeks, including 88% of patients achieving at least a 50% reduction in TSS Top-line results from Summit Part 2 registration-directed trial on track for July 2025 WALTHAM, Mass. and BOULDER, Colo.
Read More
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
• Top-line results from SUMMIT trial in NonAdvSM patients expected July 2025 • APEX trial enrollment in AdvSM patients complete; top-line results expected in 2H 2025 • Top-line results from PEAK trial in 2 nd -line GIST patients expected by end of 2025 • $312 million sufficient to fund operations well past clinical readouts, into late 2026; includes gross proceeds from ATM sale in February 2025 WALTHAM, Mass. and BOULDER, Colo.
Read More
About Cogent Biosciences, Inc. (COGT)
- IPO Date 2018-03-29
- Website https://www.cogentbio.com
- Industry Biotechnology
- CEO Mr. Andrew R. Robbins M.B.A.
- Employees 205